Please note: The University of Texas Health Science Center at San Antonio will now be called "UT Health San Antonio."

Search Program Faculty/Research

Charles Bowden, M.D.

Charles bowden

RESEARCH

Dr. Charles Bowden, clinical professor in the departments of psychiatry and pharmacology who occupies the Nancy U. Karren Endowed Chair in Psychiatry, is an internationally respected authority on bipolar disorder and mood-stabilizing medications. He is recognized in the Psychiatry/Psychology category.

Dr. Bowden’s research has defined the symptoms and biology of bipolar disorders, and he has contributed major new understandings about the effectiveness and biochemical and physiological effects of mood-stabilizing drugs. He has studied many of the newest treatments for bipolar disorder in tightly designed, randomized, controlled clinical trials that have allowed their approval by the U.S. Food and Drug Administration and wide dissemination to patients.

Notable highlights

- Recognized in Thomson Reuter’s “The World’s Most Influential Scientific Minds, 2014; and for 2015.” The honorees published the greatest number of highly cited papers (top one percent of citations by field) in 21 broad fields between 2014 and 2015. 

- Dr Bowden is one of 110 scientists worldwide recognized in the Psychiatry/psychology category and one of 8 scientists recognized whose primary research work is on bipolar disorder.

- Received the Andrew C. Leon Distinguished Career Award, The International Society for CNS Clinical Trials and Methodology, in 2016

- Served as Councilor for the International Society for Bipolar Disorders Training, Education and Research Committee in 2005

- Served on Task Force on Nomenclature and Outcome, 2007-, Task Force Expert Panel on Use of Antidepressants in Bipolar Disorders, 2012-2013, Committee on Research Diagnostic Criteria (RDC) for Bipolar Disorder 2013-, Vice President of Research, 2015

Selected Publications

Katz MM, Berman N, Bowden CL, Frazer A. The componential approach enhances the effectiveness of 2-week trials for new antidepressants J Clin Psychopharmacol 2011 Apr;31(2):253-254.

Brooks JO, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder J Clin Psychiatry 2011 Feb;72(2):240-247.

Clinical Professor, Psychiatry

Nancy U. Karren Chair of Psychiatry

Graduate Faculty, Graduate School of Biomedical Sciences

Faculty, Center for Biomedical Neuroscience

Education

M.D., Medicine, Baylor College of Medicine, 1964

B.S., Pre-med, The University of Texas at Austin, 1960

Contact

Phone: (210) 567-5405
Email: bowdenc@uthscsa.edu